Cathepsin S and cathepsin L in serum and synovial fluid in rheumatoid arthritis with and without autoantibodies

Rheumatology (United Kingdom)

Volumn 54, Issue 10, 2015, Pages 1923-1928

  Weitoft, Tomas ^a   Larsson, Anders ^a   Manivel, Vivek A ^a   Lysholm, Jörgen ^b   Knight, Ann ^c   Rönnelid, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b FALUN HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ACPA; Cathepsin L; Cathepsin S; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

C REACTIVE PROTEIN; CATHEPSIN L; CATHEPSIN S; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; PREDNISOLONE; RHEUMATOID FACTOR; STROMELYSIN;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; KNEE DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SERODIAGNOSIS; SERUM; SYNOVIAL FLUID LEVEL; SYNOVITIS;

EID: 84943754804     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu486     Document Type: Article

References (19)

1. Klareskog L, Rönnelid J, Lundberg K et al. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008;26:651-75.
2. Hsing LC, Rydensky AY. The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol Rev 2005;201:229-41.
3. Nakagawa TY, Roth W, Wong P et al. Cathepsin L: critical role in li degradation and CD4 T cell selection in the thymus. Science 1998;280:450-3.
4. Turk V, Stoka V, Vasiljeva O et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta 2012;1824:68-88.
5. Schurigt U, Eilenstein R, Gajda M et al. Decreased arthritis severity in cathepsin L-deficient mice is attributed to an impaired T helper cell compartment. Inflamm Res 2012;61: 1021-9.
6. Nakagawa TY, Brissette WH, Lira PD et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999;10:207-17.
7. Cunnane G, Fitzgerald O, Hummel KM et al. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early rheumatoid arthritis. Rheumatology 1999;38:34-42.
8. Pozgan U, Caglic D, Rozman B et al. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem 2010; 391:571-9.
9. Posthumus MD, Limburg PC, Westra J et al. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol 2000;27:2761-8.
10. Mahmoud A, Hodkinson B, Meyer P et al. Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis. Mediators Inflamm 2013;2013:183653.
11. De Rycke L, Peene I, Hoffman IEA et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63:1587-93.
12. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
13. Steinbrocker O, Traeger CH, Betterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;140: 659-62.
14. Ekdahl C, Eberhardt K, Andersson SI et al. Assessing disability in patients with rheumatoid arthritis. Scand J Rheumatol 1988;17:263-71.
15. Prevoo MLL, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
16. Larsen A, Dale K. Standardized radiological examination of rheumatoid arthritis in therapeutical trials. In: Dumonde DC, Jasani MK, eds. The recognition of antirheumatic drugs. Lancaster: MTP Press, 1978:285-92.
17. Ruge T, Södergren A, Wållberg-Jonsson S et al. Circulating plasma levels of cathepsin S and L are not associated with disease severity in patients with rheumatoid arthritis. Scand J Rheumatol 2014;43:371-3.
18. Nishimura K, Sugiyama D, Kogata Y et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797-808.
19. Harre U, Georgess D, Bang H et al. Induction of osteoclastogenesis and bone loss by human antibodies against citrullinated vimentin. J Clin Invest 2012;122:1791-802.